Sarah Bennett
In the lead-up to the 2020 US election, there were concerns that then-President Donald Trump would rush the approval of a Covid-19 vaccine in a bid to boost his campaign. This was dubbed the October surprise. The worry was that, in doing so, Trump would undermine the safety and efficacy of the vaccine, potentially causing harm and shaking the public's trust in Covid-19 vaccines. This could also have disastrous effects on future vaccine programs. One of the country's most prominent doctors, Eric Topol, led a campaign to ensure the administration could not rush a Covid-19 vaccine through regulatory authorisation before Election Day.
| Characteristics | Values |
|---|---|
| Date of publication | June 2020 |
| Author | Various |
| Main argument | Trump could rush the release of a Covid-19 vaccine before the election as a campaign stunt |
| Evidence | History of promoting hydroxychloroquine, pressure on FDA, potential for Emergency Use Authorization |
| Risks | Lack of safety and efficacy data, potential for serious outbreaks, damage to public trust in vaccines |
| Response | Advocacy by doctors and researchers, open letters, media responses |
Explore related products
What You'll Learn
Rushing the vaccine through the FDA approval process
The possibility of an "October surprise" vaccine was first raised in a New York Times editorial in June 2020. The editorial warned that a vaccine approval could turn into a "campaign stunt". Rushing a vaccine through the FDA approval process could have disastrous effects on the pandemic and future vaccine programs. It could also shake the public's trust in any COVID-19 vaccine.
To prevent this scenario, Dr. Eric Topol, a heart expert and researcher, led a campaign to ensure that the Trump administration could not rush a COVID-19 vaccine through regulatory authorization before Election Day on November 3. Topol believed that developing an effective vaccine against COVID-19 should be evaluated on the basis of scientific data, not political implications. He also pointed out that giving people a false sense of security could lead to serious outbreaks of the disease as people reduce their compliance with physical distancing and other public health measures.
Topol targeted Pfizer, the only pharmaceutical company likely to seek approval of its vaccine before Election Day. On September 25, 2020, Topol and 60 other experts signed a letter to Pfizer's CEO, asking the company not to apply for an EUA before late November when there would be more safety data. On October 16, 2020, Pfizer announced that it would not seek emergency approval for its vaccine before the third week of November, adhering to the safety standards issued by the FDA against Trump's wishes.
The FDA's Emergency Use Authorization (EUA) only requires that the agency finds it "reasonable to believe" that a vaccine "may be effective" in preventing a life-threatening illness for it to be marketed without being formally approved. An emergency authorization would have allowed Trump to hold his press conference and declare victory, similar to President George W. Bush's "Mission Accomplished" proclamation. However, millions of vaccines could have been distributed without proof of their ability to prevent or transmit the disease.
US Children: Most Vaccinated Globally?
You may want to see also
Explore related products
The potential for an October surprise
In June 2020, respected vaccinologist Paul Offit and Professor of Medical Ethics and Health Policy Ezekiel Emanuel co-authored an article in the New York Times, warning of the potential for an "October surprise" from then-President Trump. The article highlighted the possibility of Trump rushing through a Covid-19 vaccine in a bid to boost his election campaign. This move would mirror President George W. Bush's "Mission Accomplished" proclamation, which was later deemed a travesty.
The article, published four months before the 2020 election, outlined the risks of an Emergency Use Authorization by the FDA, which only requires a "reasonable belief" that a vaccine "may be effective". This authorization does not require formal licensing, and millions of vaccines could be distributed without proof of their effectiveness in preventing or transmitting the disease. The potential for a rushed vaccine to be unsafe and ineffective is extremely high, and it could have disastrous effects on the pandemic and future vaccine programs.
The authors also pointed out the danger of giving people a false sense of security, which could lead to serious outbreaks as individuals relax their compliance with physical distancing and other public health measures. This was a particular concern for healthcare professionals, who were already dealing with scepticism about vaccines and the anti-vaxx movement. The potential for a semi-successful or unsuccessful vaccine to fuel anti-vaccine sentiment was a significant worry.
The scenario outlined in the article played out in a hypothetical timeline, with a poll released by Fox News on October 23, 2020, showing Trump trailing Biden by eight points. In response, Trump could have hastily convened a news conference to announce an Emergency Use Authorization for a coronavirus vaccine by the FDA. This would have allowed him to declare victory over Covid-19 and demand an immediate reopening of all businesses, predicting a swift economic recovery.
While the article presented a hypothetical situation, it highlighted the very real possibility of Trump using a vaccine as a campaign stunt. The potential consequences of such a move could have been dire, with public health and safety at risk. The article served as a warning to the public and a reminder to approach vaccine development and emergency authorizations with caution.
Hepatitis A Vaccine: Lifetime Immunity or Booster Needed?
You may want to see also
Explore related products
The danger of a false sense of protection
The potential for a false sense of protection is a significant concern if a vaccine is rushed through the approval process and used as a campaign stunt. This scenario could play out as an "October Surprise", with an Emergency Use Authorization granted by the FDA, as it did with hydroxychloroquine. This authorization does not require formal licensing or proof of the vaccine's efficacy and safety. Millions of vaccines could be distributed without certainty that they prevent disease or transmission.
Furthermore, a semi-successful or unsuccessful vaccine promoted by the President could fuel anti-vaccine sentiment, pushing those already hesitant towards complete non-belief in vaccines. This would be detrimental to public health, not only in the context of the coronavirus pandemic but also regarding other vaccine-preventable diseases.
To avoid this danger, it is crucial that the FDA upholds the integrity of the vaccine approval process. Randomized, controlled trials and independent reviews by medical experts are essential to ensure the safety and efficacy of a vaccine before it is distributed to the public. While there is pressure to find a solution to the pandemic, rushing a vaccine without thorough evaluation could ultimately cause more harm than good.
In summary, the potential for a false sense of protection due to a hastily approved and ineffective vaccine is a serious risk if a vaccine becomes a political tool. It could undermine public health efforts, fuel anti-vaccine sentiment, and have far-reaching consequences for the pandemic response and future vaccine development. Therefore, it is imperative that the approval process remains rigorous and guided by scientific evidence to safeguard public health and trust in vaccination programs.
MMR Vaccine and Autism: Exploring the Link
You may want to see also
Explore related products
$28.78 $14.95
The possibility of an Emergency Use Authorization
In the case of the COVID-19 pandemic, the FDA faced pressure from the Trump administration to approve vaccines quickly. There were concerns that the FDA could make a hasty decision and rush the approval process, potentially compromising safety and efficacy. This was referred to as the "October Surprise," where Trump would try to rush through a vaccine approval to gain favor in the election.
However, the FDA did release guidelines for approving COVID-19 vaccines, requiring candidates to show at least 50% efficacy in placebo-controlled clinical trials. They also required manufacturers to conduct animal studies to ensure the vaccines did not worsen the infection. These guidelines were meant to address concerns about hasty decisions and ensure the safety and effectiveness of any approved vaccines.
Despite these guidelines, there were still instances where FDA officials restricted COVID vaccine approvals, going against the advice of agency staff. This included limiting the shots to certain high-risk groups instead of approving them for everyone 12 and older. Additionally, the Trump administration took actions to prohibit federal funding for COVID-19 vaccine mandates in schools, further complicating the vaccine landscape.
In conclusion, while the possibility of an Emergency Use Authorization by the FDA exists and has been considered, the final decision must be made carefully with proper evaluation of safety and efficacy data. The involvement of the Trump administration and the political landscape added complexity to the vaccine approval process, but the FDA's guidelines and independent evaluations aimed to ensure the safety and effectiveness of any approved vaccines.
The Future of Vaccines: Needle-Free Possible?
You may want to see also
Explore related products
The impact on public trust in vaccines
The potential impact on public trust in vaccines if Trump were to turn the Covid-19 vaccine into a campaign stunt is a cause for concern. There are worries that Trump could rush through a vaccine in an attempt to win favour before the election, which could have disastrous effects on the pandemic and future vaccine programs.
Firstly, the safety and efficacy of the vaccine would not be well established, and millions of vaccines could be distributed without proof that they can prevent or transmit the disease. This could lead to serious outbreaks of the disease, as people may reduce their compliance with physical distancing and other public health measures, feeling a false sense of protection.
Secondly, a semi-successful or unsuccessful vaccine could fuel anti-vaccine sentiment and turn those who are already hesitant into complete non-believers in vaccines in general. This could have long-lasting effects on public health, as vaccine programs could become less trusted and less effective.
Furthermore, the public's trust in the drug approval process could be damaged if the FDA were to issue an Emergency Use Authorisation without sufficient evidence of the vaccine's safety and efficacy. This could lead to a loss of faith in the FDA and other regulatory bodies, potentially causing harm to public health in the long term.
Finally, Trump's potential declaration of victory over Covid-19 and demand for all businesses to reopen could cause further damage to public trust. If the vaccine were not adequately tested and proven effective, this proclamation could be seen as a travesty and a political stunt, damaging the public's trust in both the vaccine and the government's handling of the pandemic.
China's Vaccine Manufacturing: Global Impact and Questions
You may want to see also
Frequently asked questions
The "October Surprise" is the possibility that Trump will rush through a Covid-19 vaccine in order to win favour before the election.
Safety and efficacy may not be well established, which could have disastrous effects on the pandemic and on future vaccine programs. It could also fuel anti-vaccine sentiment.
After being released from the hospital, Trump promised that the public would soon have a vaccine against Covid-19.
Eric Topol, a heart expert and researcher, led online calls for FDA commissioner Steve Hahn to resign, citing that the agency had bowed to political pressure. He also targeted Pfizer, the company most likely to seek approval before the election. On October 16, Pfizer announced it would not be able to seek emergency approval before the third week of November, due to safety standards.
The FDA can issue an Emergency Use Authorization if it finds it "reasonable to believe" that a vaccine "may be effective" in preventing a life-threatening illness. An emergency authorization would allow Trump to declare victory, but it could be a travesty if millions of vaccines are distributed without proof of their effectiveness.
